Environmental monitoringprogram is deficient to ensure environments are classified and controlled to manufacture (b)(4) DS.
Inspection Record
Andelyn Biosciences, Inc. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Quality oversight is inadequate to ensure (b)(4) drug substance (DS) has the | 7 (b)(4) it purports or is represented to possess.
Disinfectant efficacy studies are inadequate to mitigate contamination and cross-contamination.
Procedures regarding out of specification results described in sop, tby(4) Laboratory Investigation Management, are inadequate.
Monitoring of utilities is deficient.
Qualification of areas used to manufacture (b)(4) DS is not adequate.
A record as of the US FDA document published on 2026-10-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.